BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Immunetrics, Inc. Technology Accelerates Development Of University of Pittsburgh Animal Model


10/19/2005 5:12:47 PM

PITTSBURGH, Feb. 21 /PRNewswire/ -- Researchers at the University of Pittsburgh have reduced time, cost, and the use of experimental animals in the development of a novel disease model by employing computer simulation technology developed by the University and licensed by Immunetrics Inc.

The use of the Immunetrics biosimulation platform represents the first known case of applying in silico technology to the development of an animal model, according to Steve Chang, chief executive officer of Immunetrics. By using simulation to help design in vivo experiments, the Pitt researchers completed development of the mouse model using a much smaller number of animals in a shorter amount of time than would have been possible without using simulation.

The goal of the Pitt animal model was to define a set of trauma conditions that would lead to reproducible inflammation and severe dysfunction but not death. The new model will be useful in studying a range in the effect of traumas in humans and other animals. Developers of the new model include Drs. Yoram Vodovotz and Claudio Lagoa, who work in the Department of Surgery at the University of Pittsburgh.

The Immunetrics technology was able to predict the severity of illness based on the duration of hemorrhage and extent of bone fracture in the species," said Timothy Billiar, M.D., chair of the Surgery Department at the University of Pittsburgh. "This permitted our lab to conduct a reduced number of experiments on a smaller number of animals in our goal to develop a very complex animal model."

The Immunetrics biosimulation technology and mathematical modes of inflammation may be used to predict the effects of infection, trauma, and hemorrhage in a large number of experimental scenarios, including drug administration. The model has been validated and calibrated in rodents and humans.

Though developed principally to help design human trials for inflammation- related drugs, the Immunetrics technology demonstrated, in the Pitt study, that computer modeling can promote the "Three R's" of experimental animal use: refinement, reduction, and replacement.

Said Chang: "Using computer models of disease systems can support the ethical emphasis on reducing the use of experimental animals, while also reducing cost and increasing speed in biological research."

Dr. Vodovotz is an inventor of the computer model, which has been licensed to Immunetrics. Drs. Billiar and Vodovotz are consultants to Immunetrics, Inc. and hold equity in Immunetrics.

About Immunetrics:

Immunetrics is a Pittsburgh-based biosimulation company providing a platform to model complex biological systems. Immunetrics possesses the first known comprehensive model of inflammation, which includes major elements of the acute and adaptive components, the coagulation cascade and matrix metalloproteases. With this model, Immunetrics can help drug companies prioritize and design preclinical and clinical programs for new therapies. Immunetrics was founded by LaunchCyte LLC and has been funded by Innovation Works, the University of Pittsburgh Medical Center, the University of Pittsburgh, private investors and the Pittsburgh Life Sciences Greenhouse (PLSG).

Pittsburgh Life Sciences Greenhouse

CONTACT: Steven Chang, Chief Executive Officer of Immunetrics Inc.,+1-412-770-1311, or steve@immunetrics.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES